Open-label Phase I Study of ET190L1-ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma

Trial Profile

Open-label Phase I Study of ET190L1-ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Dec 2017

At a glance

  • Drugs ET190L1-ARTEMIS T cell (Primary)
  • Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Eureka Therapeutics
  • Most Recent Events

    • 29 Nov 2017 New trial record
    • 27 Nov 2017 According to an Eureka Therapeutics media release, the company today announced U.S. Food and Drug Administration (FDA) allowance of its investigational new drug (IND) application and authorization to commence a Phase I clinical trial
    • 27 Nov 2017 According to an Eureka Therapeutics media release, the Principal Investigator for this trial is David A. Rizzieri, M.D., Professor of Medicine, Section Chief of Hematologic Malignancies and Associate Director for Clinical Research at the Duke Cancer Institute, Duke University School of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top